Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902381 · ClinicalTrials.gov registry record · Phase 2
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01902381 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 12 participants.
The verdict
NCT01902381, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating patients with myelodysplastic syndromes who failed previous therapy. Sometimes when chemotherapy or biological therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to treatment. 6, 8-bis (benzylthio) octanoic acid may interfere with the growth of tumor cells and may be an effective treatment for myelodysplastic syndromes that did not respond to previous therapy.
Interventions
- DRUG 6,8-bis(benzylthio)octanoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01902381
The ClinicalTrials.gov registry entry for NCT01902381 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6,8-bis(benzylthio)octanoic acid is the first listed.
NCT01902381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01902381 about?
NCT01902381 is a clinical study titled "CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy". This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating patients with myelodysplastic syndromes who failed previous therapy. Sometimes when chemotherapy or biological therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant t...
What is the current status of trial NCT01902381?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-08. Estimated completion is 2018-11-26.
What interventions are being tested in trial NCT01902381?
The interventions under investigation include: 6,8-bis(benzylthio)octanoic acid (DRUG).
Who is sponsoring clinical trial NCT01902381?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.